+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Factor IX"

Hemophilia B (Factor IX Deficiency) Global Clinical Trials Review, H2, 2019 - Product Thumbnail Image

Hemophilia B (Factor IX Deficiency) Global Clinical Trials Review, H2, 2019

  • Clinical Trials
  • December 2019
  • 173 Pages
  • Global
From
Hemophilia: Epidemiology Forecast to 2028 - Product Thumbnail Image

Hemophilia: Epidemiology Forecast to 2028

  • Report
  • July 2019
  • 48 Pages
  • Global
From
Coagulation Factor XI - Pipeline Review, H2 2020 - Product Thumbnail Image

Coagulation Factor XI - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 71 Pages
  • Global
From
Hemophilia B (Factor IX Deficiency) - Pipeline Review, H2 2020 - Product Thumbnail Image

Hemophilia B (Factor IX Deficiency) - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 159 Pages
  • Global
From
Loading Indicator

Factor IX is a protein used to treat hemophilia B, a rare genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of the human factor IX protein, which is produced in a laboratory setting. Factor IX is administered intravenously or subcutaneously to replace the missing clotting factor in patients with hemophilia B. It is used to prevent and treat bleeding episodes, as well as to prevent bleeding during surgery. Factor IX is a part of the larger hematological drugs market, which includes drugs used to treat blood-related diseases and disorders. These drugs are used to treat a wide range of conditions, including anemia, leukemia, and thrombocytopenia. Some companies in the Factor IX market include Novo Nordisk, Pfizer, Bayer, and Biogen. Show Less Read more